Last reviewed · How we verify
House dust mite Novo Helisen Depot
House dust mite allergen extract that desensitizes the immune system through repeated subcutaneous administration to reduce allergic responses.
House dust mite allergen extract that desensitizes the immune system through repeated subcutaneous administration to reduce allergic responses. Used for House dust mite allergy (allergic rhinitis and/or allergic asthma).
At a glance
| Generic name | House dust mite Novo Helisen Depot |
|---|---|
| Sponsor | Allergopharma GmbH & Co. KG |
| Drug class | Allergen immunotherapy |
| Modality | Biologic |
| Therapeutic area | Immunology / Allergy |
| Phase | FDA-approved |
Mechanism of action
This is an allergen immunotherapy (AIT) product containing standardized house dust mite allergen extract. It works by gradually exposing the immune system to increasing doses of the allergen, promoting immune tolerance through shift toward regulatory T cells and anti-inflammatory responses. The depot formulation provides sustained release to maintain therapeutic allergen levels.
Approved indications
- House dust mite allergy (allergic rhinitis and/or allergic asthma)
Common side effects
- Local injection site reactions (erythema, swelling, pruritus)
- Systemic allergic reactions
- Anaphylaxis
Key clinical trials
- Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites
- Intratonsillar Immunotherapy for Allergic Rhinitis (NA)
- Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis (PHASE4)
- Evaluation of Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma (PHASE4)
- Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- House dust mite Novo Helisen Depot CI brief — competitive landscape report
- House dust mite Novo Helisen Depot updates RSS · CI watch RSS
- Allergopharma GmbH & Co. KG portfolio CI